Peptide Comparison
UlaritidevsNesiritide (BNP)
A synthetic natriuretic peptide designed to help your heart pump better and remove excess fluid when you need it most.
Recombinant B-type natriuretic peptide that helps your heart breathe easier by reducing fluid overload and improving blood flow during acute heart failure crises.
At a Glance
Quick
comparison
Dose Range
Ularitide
As prescribed–As prescribed mg
Nesiritide (BNP)
0.01 mcg/kg/min–0.03 mcg/kg/min mcg
Frequency
Ularitide
Once daily
Nesiritide (BNP)
Once daily
Administration
Ularitide
Intravenous infusion
Nesiritide (BNP)
Intravenous (IV) bolus
Cycle Length
Ularitide
Ongoing/indefinite
Nesiritide (BNP)
Ongoing/indefinite
Onset Speed
Ularitide
Moderate (1-2 weeks)
Nesiritide (BNP)
Moderate (1-2 weeks)
Evidence Level
Ularitide
Strong human trials (Phase 3 or FDA approved)
Nesiritide (BNP)
Strong human trials (Phase 3 or FDA approved)
Efficacy
Benefit
ratings
Cardiovascular Support
Fluid & Electrolyte Balance
Kidney Protection
Rapid Symptom Relief
Fluid Management
Heart Workload Reduction
Technical Data
Compound
specifications
Ularitide
Molecular Formula
C145H234N52O44S3
Molecular Weight
3505.9
Half-Life
6-7 minutes (in circulation)
Bioavailability
100% (intravenous administration)
CAS Number
Not publicly assigned (proprietary compound)
Nesiritide (BNP)
Molecular Formula
C143H244N50O42S4
Molecular Weight
3464.0 Da
Half-Life
18 minutes (terminal elimination half-life)
Bioavailability
100% (intravenous administration)
CAS Number
114471-18-0
Applications
Best
suited for
Ularitide
Managing acute heart failure symptoms and fluid overload
Ularitide is particularly well-suited for individuals focused on managing acute heart failure symptoms and fluid overload. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving oxygen delivery when your heart can't pump efficiently
Ularitide is particularly well-suited for individuals focused on improving oxygen delivery when your heart can't pump efficiently. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Protecting kidney function in critical heart patients
Ularitide is particularly well-suited for individuals focused on protecting kidney function in critical heart patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Nesiritide (BNP)
Emergency stabilization of acute heart failure episodes
Nesiritide (BNP) is particularly well-suited for individuals focused on emergency stabilization of acute heart failure episodes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Rapid relief of severe shortness of breath
Nesiritide (BNP) is particularly well-suited for individuals focused on rapid relief of severe shortness of breath. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing hospitalization time and improving outcomes
Nesiritide (BNP) is particularly well-suited for individuals focused on reducing hospitalization time and improving outcomes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing sudden fluid buildup in the lungs or legs
Nesiritide (BNP) is particularly well-suited for individuals focused on managing sudden fluid buildup in the lungs or legs. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Ularitide
Common
- Dizziness or lightheadedness
- Low blood pressure (hypotension)
- Headache
- Nausea
Uncommon
- Elevated potassium levels
- Worsening kidney function (transient)
- Allergic reactions at injection site
- Chest discomfort
- Irregular heartbeat (arrhythmia)
Serious
- Severe hypotension requiring intervention
- Worsening heart function in some patients
- Acute kidney injury (rare)
- Anaphylactic shock (very rare)
Nesiritide (BNP)
Common
- Headache
- Lightheadedness
- Back pain
Uncommon
- Hypotension (low blood pressure)
- Abdominal pain
- Insomnia
Serious
- Acute kidney injury
- Severe hypotension
- Allergic reaction
Research Status
Safety
& evidence
Ularitide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Not FDA approved
Safety Overview
Ularitide is a recombinant B-type natriuretic peptide approved in Europe for acute heart failure with safety data from Phase 3 trials showing favorable tolerability compared to placebo and nesiritide. Hypotension is the primary dose-limiting adverse effect, requiring baseline blood pressure assessment and careful hemodynamic monitoring during IV infusion. Natriuretic peptide class risks include worsening renal function in some patients and hypokalemia (electrolyte abnormalities from enhanced diuresis), necessitating electrolyte monitoring during acute phase therapy.
Contraindications
- xHypotension (dangerously low blood pressure)
- xCardiogenic shock without proper monitoring
- xSevere renal dysfunction in some cases
- xAllergy to synthetic peptides
Nesiritide (BNP)
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
FDA-approved nesiritide (Natrecor) demonstrates excellent safety in acute decompensated heart failure with rapid onset (15-minute half-life providing quick reversibility). Symptomatic hypotension occurs in 11% of patients, managed through continuous IV monitoring and dose titration. No serious adverse events, carcinogenicity, or renal dysfunction directly attributable to nesiritide in Phase III trials (n=700+). Tachyphylaxis (tolerance) can develop with prolonged infusions beyond 24-48 hours.
Contraindications
- xSystolic blood pressure less than 90 mmHg
- xSevere renal impairment or kidney disease
- xCardiogenic shock or severe hypotension
- xAllergy to nesiritide or any ingredients
Decision Guide
Which is
right for you?
Choose Ularitide if...
- Managing acute heart failure symptoms and fluid overload
- Improving oxygen delivery when your heart can't pump efficiently
- Protecting kidney function in critical heart patients
Choose Nesiritide (BNP) if...
- Emergency stabilization of acute heart failure episodes
- Rapid relief of severe shortness of breath
- Reducing hospitalization time and improving outcomes
- Managing sudden fluid buildup in the lungs or legs